摘要
目的:探索25羟维生素D[25(OH)D]与2型糖尿病(type 2 diabetes mellitus,T2DM)合并桥本氏甲状腺炎(Hashimoto’s thyroiditis,HT)患者临床指标之间的关联。方法:选取T2DM合并HT患者、T2DM患者及健康体检者各100例,收集所有研究对象的年龄、性别、身高、体重等一般资料,检测空腹血糖(fasting blood-glucose,FBG)、血脂、肝功能、糖化血红蛋白(HbA1c)、游离三碘甲状腺原氨酸(free triiodothyronine 3,FT_(3))、游离甲状腺素(free thyroxine,FT_(4))、促甲状腺激素(thyroid-stimulating hormone,TSH)、甲状腺过氧化物酶抗体(thyroid peroxidase antibody,TPOAb)、甲状腺球蛋白抗体(thyroglobulin antibody,TGAb)及25(OH)D的浓度,探索25(OH)D与各组指标之间的关联性,并且采用中介效应模型分析其中可能的中介因子。结果:T2DM+HT组中,HbA1c、C反应性蛋白(C-reactive protein,CRP)、TPOAb、TGAb及TG与25(OH)D均呈负相关,高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)与25(OH)D呈正相关,在25(OH)D导致HbA1c降低的过程中,CRP介导了20.04%的效应;同样,HbA1c介导了25(OH)D降低TGAb过程中12.04%的效应。结论:25(OH)D影响T2DM合并HT患者疾病的进展,CRP及HbA1c在其过程中发挥重要作用。
Objective:To explore the association between 25-hydroxyvitamin D[25(OH)D]and clinical indicators in patients with type 2 diabetes mellitus(T2DM)combined with Hashimoto’s thyroiditis(HT).Methods:We selected 100 patients with T2DM combined with HT,100 patients with T2DM and 100 healthy subjects,and collected general data such as age,sex,height,and weight of all study subjects,and measured fasting blood-glucose(FBG),blood lipids,liver function,HbA1c,free triiodothyronine 3(FT_(3)),free thyroxine(FT_(4)),thyroid stimulating hormone(TSH),thyroid peroxidase antibody(TPOAb),thyroglobulin antibody(TGA),and thyroid glucose.We also explored the correlation between 25(OH)D and each group of indicators and analyzed the possible mediators among them using a mediating effect model.Results:In the T2DM+HT group,HbA1c,C-reactive protein(CRP),TPOAb,TGAb and TG were negatively correlated with 25(OH)D,high-density lipoprotein cholesterol(HDL-C)was positively correlated with 25(OH)D,and CRP mediated 20.04%of the effect of 25(OH)D in causing a decrease in HbA1c.Meanwhile,HbA1c mediated 12.04%of the effect during the reduction of TGAb due to 25(OH)D.Conclusion:25(OH)D affects disease progression in T2DM+HT patients,with CRP and HbA1c playing an important role in the process.
作者
方芳
李刚
汤华萍
FANG Fang;LI Gang;TANG Huaping(Department of Geriatric Medicine,Ma’anshan First People’s Hospital,Ma’anshan Anhui 243099,China)
出处
《临床与病理杂志》
CAS
2022年第9期2235-2241,共7页
Journal of Clinical and Pathological Research
基金
马鞍山医疗卫生领域科技计划项目(YL-2021-03)。
